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Efficacy and variability of the antiproteinuric effect of ACE inhibition
by lisinopril. We studied the efficacy of the ACE inhibitor lisinopril in
treating overt proteinuria in comparison with the NSAID indomethacin,
and evaluated some of the conditions that could influence this antipro-
teinuric effect. In 12 patients with a proteinuria varying from 3.2 to 10.5
g/24 hr, a diastolic BP ranging from 64 to 105 mm Hg, and a GFR
varying from 34 to 127 ml/min, the effect of different lisinopril doses and
of changing dietary sodium intake was evaluated. Proteinuria fell by 27
20% from 6.1 2.1 to 4.5 1.9 g124 hr on a low dose (median 5
mg/day) lisinopril and by 50 17% to 3.1 1,4 g/24 hr on a higher dose
(median 10 mg/day), irrespective of initial proteinuria, BP, or GFR.
This antiproteinuric effect was abolished by increasing salt intake from
50 to 200 mmol/day, and was recovered again by re-instituting the
sodium restricted diet. The antiproteinuric effect of 10 mg/day lisinopril
was comparable to the reduction in proteinuria (by 57 21% to 2.8
2.0 g/24 hr) on 150 mg/day indomethacin, while adverse effects were
less and renal hemodynamic effects were more favorable during lisino-
pril. In some patients it took several weeks before the effect of the ACE
inhibitor on proteinuria was stabilized. Thus, the antiproteinuric effect
of the ACE inhibitor lisinopril appears to be dose and time related, and
is strongly dependent on dietary sodium restriction, whereas it does not
depend on initial proteinuria, BP, or GFR. The effect is comparable to
that of indomethacin, while adverse effects are less.
Angiotensin converting enzyme (ACE) inhibitors have a well
established antihypertensive effect, in essential hypertension
[1] as well as in renal disease [2]. This effect is associated with
renal hemodynamic effects [3]. In addition, it has recently been
shown by several investigators that ACE inhibitors can reduce
urinary protein excretion in patients with renal disease of
various origin [4—10]. However, individual responses appear to
vary considerably from a rise of 31% to a fall of 100% in urinary
protein excretion [5, 6, 8—10], and in other studies no lowering
of proteinuria by ACE inhibition was found [11—131. This may
be due to parameters like the use of different doses of ACE
inhibitor, varying concurrent antihypertensive (or diuretic)
medication and non-standardized dietary sodium intake. Also
the degree of pretreatment proteinuria varied considerably.
Moreover, in studies concerning nephrotic range proteinuria
only patients with hypertension and with impaired renal func-
tion have thus far been studied. The question thus remains
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whether ACE inhibitors may be useful in treatment of protein-
uria per se. Until now, only non-steroidal anti-inflammatory
drugs (NSAID's) like indomethacin are available to reduce
non-steroid-sensitive proteinuria [14, 15]. However, the use of
these agents may be limited by the adverse effects on renal
function [14—16] and by further side effects, especially in the
digestive tract.
The present study was undertaken to establish the efficacy of
the ACE inhibitor lisinopril in treating overt proteinuria in
comparison with the NSAID indomethacin, and to evaluate
some of the different conditions that could influence this an-
tiproteinuric effect. The study was performed in a prospective
open design, in which the patients alternately received both
therapies, each preceded by a control period. In an attempt to
eliminate any possible effects of blood pressure lowering per se
on proteinuria, a-methyldopa was given to lower blood pres-
sure during the control periods and during indomethacin ther-
apy. In the first part of the study, the dose of lisinopril was
titrated to reach a blood pressure comparable to that obtained in
the previous periods on a-methyldopa. In the second part of the
study, the dose of lisinopril was increased to establish whether
the antiproteinuric effect was dose-related. Moreover, the in-
fluence of pretreatment parameters such as blood pressure,
renal function and proteinuria was evaluated. Finally, in the
third part of the study, the influence of dietary sodium intake on
proteinuria during ACE inhibition was studied.
Methods
Patients
The study was approved by the local Medical Ethical Com-
mittee, and all patients gave their informed consent. The
patients had non-steroid sensitive proteinuria of more than 3
g/24 hr and a glomerular filtration rate (GFR) of more than 30
mI/mm, being relatively stable the year before the study. To
avoid drop out during the control periods, the patients had to be
able to be without diuretic or other vasoactive therapy during
the study. Steroid or other immunosuppressive therapy was not
allowed. Twelve patients were enrolled in the study (5 female,
7 male) with a mean age of 39 years (range 26 to 56). The
characteristics of these patients are given in Table 1. They had
renal disease of different etiology all proven by renal biopsy. All
medication was withdrawn at least two weeks before entry into
the study. Proteinuria without medication ranged from 3.2 to
10.5 with a mean of 6.0 2.3 g/24 hr. Blood pressure was 134
13 mm Hg systolic and 84 13 mm Hg diastolic. Diastolic
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Table 1. Patient characteristics at entry (without therapy)
Blood
No Sex Age Diagnosis
Pro-
teinuria
g/24 hr
pressure
(and MAP)
mm Hg
Creatinine
clearance
mi/mm
I f 34 no diagnosis 3.5 135/91 (106) 109
2 m 26 IgA nephropathy 5.6 127/77 (94) 103
3 m 51 mgp 7.1 128/76 (94) 73
4 f 39 glom.sclerosis 9.3 129/90 (103) 50
5 m 48 mgp 3.2 153/lOS (121) 126
6 m 56 mgp 6.5 155/90 (112) 104
7 m 52 mgp 5.6 128/81 (96) 92
8 f 29 mgp 4.5 120/68 (85) 81
9 f 32 glom.sclerosis 3.3 119/64 (82) 137
10 m 52 mgp 10.5 154/103 (120) 65
11 f 27 nsr-mcd 6.4 123/89 (100) 65
12 m 26 loc.foc.gn 6.5 132/74 (93) 100
Mean: 39 6.0 134/84 (101) 92
six 12 2.3 13/13 (12) 26
Abbreviations are: mgp, membranous glomerulopathy; glom . sclero-
sis, glomeruloscierosis; nsr-mcd, non-steroid responsive minimal
change disease; loc.foc.gn, local focal glornerulonephritis without sys-
temic disease.
blood pressure ranged from 64 to 105 mm Hg and was >95 mm
Hg in only two patients.
Study protocol
The study was performed on an ambulatory basis. A dietary
intake of 50 mmol sodium chloride per day was prescribed for
all patients as well as a 60 g/day protein intake for the patients
with a reduced renal function. The protein content of the diet
was not changed during the study. Patient compliance to this
dietary advice was assessed by measuring urinary sodium and
urea excretion. All patients visited the outpatient clinic every
one or two weeks. During each visit body weight and blood
pressure were measured, and blood was drawn for determina-
tion of serum electrolytes, creatinine, and albumin. Urinary
protein, sodium, urea and creatinine were measured in a
24-hour urine sample collected the previous day. Each of the
study periods in which the different pharmacological or dietary
manipulations were evaluated, lasted until stability in blood
pressure and proteinuria was reached. Stability in these param-
eters was assumed when no continuing rise or fall occurred
during the last three visits, and when diastolic blood pressure
did not vary more than 5 mm Hg and urinary protein excretion
did not vary more than 15%. The study period was concluded
with three ambulatory days of 24-hour urine collections and an
in-hospital test day. The effect of therapy on the different
parameters in each period was evaluated using the mean of
these three consecutive 24-hour urine collections combined
with the 24-hour urine samples of the two preceding ambulatory
visits. During the test days the patients remained supine, and
GFR and effective renal plasma flow (ERPF) were measured.
Blood was drawn at 8 a.m., just before the medication was
taken, to determine serum ACE activity, serum electrolytes,
creatinine, and albumin.
The study is divided in different parts, which respectively
dealt with the different objectives of the study. In part I the
effect of lisinopril is compared to the effect of indomethacin. All
12 patients went through this part of the study, which consisted
of four periods: (I) a control period, in which c-methyldopa 125
to 500 mg t.i.d. was prescribed, titrated to reduce mean arterial
blood pressure (MAP) by 10 mm Hg as compared to the
preceding period without medication; (II) the indomethacin
period, in which indomethacin 150 mg/day was added to the
a-methyldopa (if necessary, the dose of a-methyldopa was
adjusted to keep blood pressure stable); (III) a second control
period, in which again only a-methyldopa was prescribed; (IV)
the lisinopril period, in which after discontinuing the a-methyl-
dopa, lisinopril 5 mg/day was started when initial diastolic blood
pressure was <90 mm Hg and 10 mg/day when diastolic blood
pressure was 90 mm Hg. The dose of lisinopril was titrated to
achieve a similar blood pressure lowering effect as was obtained
with a-methyldopa in the preceding periods.
In part 2, the effect on proteinuria of doubling the lisinopril
dose in a next study period was studied in 9 of the 12 patients.
Subsequently, the data of all 12 patients were evaluated study-
ing whether initial blood pressure, GFR or proteinuria deter-
mined the antiproteinuric response. For this reason cut-off
points were chosen to divide the patients in two equal-sized
groups. When stratified according to blood pressure, six pa-
tients had a mean arterial pressure (MAP)  100 mm Hg and six
had a MAP <100 mm Hg without therapy. There were six
patients with a GFR 75 mI/mm and six with a GFR <75
mI/mm; six had a protein excretion 6 g/24 hr and six had <6
g124 hr.
In part 3, without changing the lisinopril dose, nine patients
switched from the sodium restricted diet (50 mmollday) to a
high sodium intake (200 mmol/day) in a next study period after
which the sodium intake was restricted again (50 mmol/day), to
evaluate the effect of dietary sodium intake on the antiprotein-
uric effect.
Methods
Blood pressure was measured at one minute intervals by a
DinamapR recorder after 10 minutes of supine rest. The mean
value of at least five readings was recorded. MAP was calcu-
lated as the diastolic blood pressure plus one-third of the pulse
pressure. Serum and urinary electrolytes, urea and creatinine,
as well as serum albumin and cholesterol, were measured by a
standard autoanalyzer (SMA-C, TechniconR). Urinary protein
was analyzed by biuret method. Serum ACE activity was
measured using a HPLC assisted assay [17].
GFR and ERPF were measured by constant infusion of
'251-iothalamate and '311-hippuran, respectively [18]. Both pa-
rameters were corrected for standard body surface area (1.73
m2). The coefficient of variation of this method is 2.2 and 5.0%,
respectively. Filtration fraction (FF) is given as the quotient of
GFR and ERPF. Renal vascular resistance (RVR) is calculated
as the ratio of MAP and ERPF.
Statistical analysis of the different parameters in the subse-
quent study periods was performed using a one-way analysis of
variance, followed by Student's t-test to compare the different
study periods. Comparison of the data when stratified according
to respectively blood pressure, renal function and proteinuria
was performed using a two-way analysis of variance. Data are
given as mean standard deviation (SD), unless otherwise
indicated. Significance was assumed at a P value of less than
5%.
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Table 2. Mean SD and mean percentage change from the
four s
preceding control period (in pa
tudy periods in 12 patients
rentheses) of the different parameters during the
Period
I
a-Methyldopa
IL
a-Methyldopa +
indomethacin
III
a-Methyldopa
IV
Lisinopril
MAPmmHg
Proteinuria g/24 hr
GFR mi/mm
ERPF mI/mm
FF %
RVR mm Hg/mI/mm
Serum creatinine jmoI/liter
Creatinine clearance mI/mm
Urinary sodium mmol/day
Urinary urea mmol/day
ACE activity U/liter
91±10
6.0 1.9
74 27
347 96
21.4 4.4
0.29 0.11
115 29
93 28
81 23
349 72
27 7
91±10(0)
2.8 2.0 (_57)c
58 22 (—19)"
288 87 (—17)"
20.3 4.1 (—4)
0.35 0.15 (+22)"
141 37 (+22)c
76 23 (— 19)C
78 28 (— I)
347 71(0)
28 9 (+1)
89±8
6.1 2.1
75 25
348 98
21.7 3.7
0.28 0.09
116 34
93 28
86 35
359 81
25 7
86±8(_3)a
4.5 1.9 (_27)c
73 26 (3)
369 99 (+7)a
19.8 3.6 (_8)a
0.26 0.09 (_8)a
116 33 (0)
90 25 (—1)
83 31 (+6)
370 114 (+2)
6 3 (7l)c
P < 0.05
b p < 0.01
P < 0,001
Results
Part I
In the first part of the study lisinopril was compared to
indomethacin with respect to the effect on proteinuria and renal
function at comparable blood pressure levels. Before the final
testday of each study period blood pressure and proteinuria had
to be stabilized. During indomethacin the effect on proteinuria
was generally established and stable from the first control visit
(1 or 2 weeks after the start of therapy), while during lisinopril
it usually took more time before urinary protein excretion had
stabilized. The median duration of the study period on lisinopril
was 10 weeks (range 5 to 13), while the indomethacin period
took seven weeks (range 4 to 9). Mean daily dose of a-
methyldopa was 760 472 mg in period I, 823 466 mg in
period II, and 781 388 mg in period III. The daily dose of
lisinopril was 2.5 mg in two patients, 5 mg in seven patients, 10
mg in two patients, and 20 mg in one patient. The results are
summarized in Table 2. The two control periods did not differ
significantly in any of the measured parameters. Blood pressure
was reduced from 134 13/84 13 without therapy to 124
11/74 10 mm Hg on a-methyldopa, a 10 7% (P < 0.001)
reduction in MAP. During the indomethacin period MAP re-
mained unchanged. However, in spite of the aim to keep the
blood pressure similar during the lisinopril period, MAP was
reduced by 3 4% as compared to the preceding control
period, and by 4 5% as compared to the indomethacin period
(both P < 0.05).
Despite the 10% blood pressure lowering, proteinuria did not
decrease during a-methyldopa, whereas it was lowered by 57
21% (P < 0.001) after addition of indomethacin. During lisino-
pril proteinuria fell by 27 20% (P < 0.001), which was
significantly less than the decrease in proteinuria on indometh-
acm (P < 0.01). In Figure 1 the individual data on proteinuria
are shown. Fractional protein excretion, calculated to account
for changes in creatinine clearance during the study, showed a
47 24% fall in indomethacin and a 26 18% fall on lisinopril
(both P < 0.001).
GFR ranged from 34 to 127 mI/mm, and was reduced by 19
19% (P < 0.01) on indomethacin, whereas GFR on lisinopril
remained stable (—3 6%, NS). ERPF decreased by 17 13%
(P <0.01) during indomethacin, while ERPF rose by 7 9% (P
< 0.05) on lisinopril. FF had not changed significantly during
indomethacin (—4 16%, NS), while FF fell by 8 9% (P <
0.05) on lisinopril. The RVR increased by 22 20% (P < 0.01)
on indomethacin and was lowered by 8 9% (P < 0.05) on
lisinopril. Serum creatinine was elevated by 22 9% and
creatininc clearance was reduced by 19 8% (both P < 0.001)
during indomethacin, whereas lisinopril did not affect these
parameters.
Since the antiproteinuric effect of lisinopril was much less
compared to indomethacin, it could be questioned whether
higher doses might have a more pronounced effect. It should be
noticed that a nearly maximal dosage of indomethacin was
used, while the dosage of lisinopril was, due to the study design,
restricted by the blood pressure lowering effect of this agent.
Part 2
In nine patients who had used only 2.5 or 5 mg lisinopnl per
day (and who were stable in urinary protein excretion on that
therapy), the lisinopril dose was increased to 10 mg/day (except
for one patient in whom the dose was doubled to 5 mg). The
median duration of this study period was 10 weeks (range 7 to
20). All these patients were normotensive with a mean pretreat-
ment blood pressure of 130 11/79 10 mm Hg, and a MAP of
96 9 mm Hg. Pretreatment proteinuria was 5.5 1.4 g/24 hr.
The effects of the different treatment modalities on urinary
protein excretion are shown in Figure 2. The individual data on
proteinuria during treatment with the higher dose of lisinopril
are also included in Figure 1. In all but one patient the
antiproteinuric effect became more pronounced. Proteinuria fell
from 5,9 1.7 on a-methyldopa to 4.8 1.7 g/24 hr on low dose
lisinopril and to 2.9 1.2 g/24 hr on the higher dose. The
reduction in protein excretion on this dose of lisinopril was 50
17% (P < 0.001), which did not differ significantly from the 56
18% (P <0.001) fall in proteinuria (from 5,7 1.5 to 2.6 1.6
g/24 hr) on indomethacin in these nine patients. The fall in
fractional proteinuria was 46 20% and 48 18% (both P <
0.001), respectively.
The further decrease in proteinuria on the higher dose of
lisinopril coincided with a further fall in blood pressure. MAP
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Fig. 1. Urinary protein excretion in the 12 patients
during the different study periods. Only 9 patients
____________ __________ __________ are included in the period with the high lisinopril
dose. The values are the means of the five 24-hour
urine collections obtained during the last month of
each study period.
Fig. 2. Proteinuria in 9 patients who received
different doses of lisinopril. The bars represent
the mean with SEM of protein excretion in the
24-hour urine collections in the last month of the
different study periods. The wide bars represent
the mean of three consecutive urine samples
prior to the testdays, whereas the narrow bars
represent the values of the two preceding
ambulatory visits.
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fell from 88 9 mm Hg in the preceding control period (with
a-methyldopa), to 84 8 mm Hg on the low dose and to 81
8 mm Hg on the higher dosage of lisinopril [a decrease of 4
4% (P < 0.05) and 7 4% (P < 0.001), respectively]. However,
in these patients a fall in MAP by 8 5% from 96 9 mm Hg
pretreatment to 88 9 mm Hg on a-methyldopa had not
resulted in any fall in proteinuria. Moreover, there was no
correlation between the lisinopril induced decrease in protein-
uria and the fall in MAP (r = 0.34, NS). As shown before, the
fall in proteinuria on indomethacin coincided with a fall in GFR
(from 78 25 to 61 23 mI/mm, P < 0.01), whereas only during
the higher dose of lisinopril, a small albeit significant fall in GFR
was observed (from 78 25 during a-methyldopa and 77 25
on low dose lisinopril to 73 23 mI/mm on the higher dose
lisinopril, P <0.01). ERPF fell on indomethacin (from 367 91
to 306 86 ml/min, P < 0.01), whereas it increased during the
N
+
Methyldopa Methyldopa Methyldopa Low dose High dose
indometh lisinopril lisinopril
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Table 3. Proteinuria (g/24 hr) and mean percentage changes from the preceding control periods (in parentheses) in different subgroups
stratified according to mean arterial blood pressure (MAP), GFR, and proteinuria (prot)
Control Indomethacin Control Lisinopril
All patients (N = 12) 6.0 1.9 2.8 2.0 (—57 21%) 6.1 2.1 3.1 1.4 (—50 17%)
MAP > 100 mm Hg (N = 6) 6.3 2.3 3.4 2.4 (—52 26%) 6.4 2.3 3.4 1.9 (—49 15%)
MAP < 100mm Hg (N = 6) 5.7 1.6 2.2 1.3 (—62 17%) 5.9 1,9 2.8 0.9 (—50 19%)
GFR > 74 mI/mm (N = 6) 4.6 1.2 1,5 0.7 (—69 15%) 5.1 2.0 2.4 1.0 (—53 19%)
GFR <74 mI/mm (N = 6) 7.4 1.4 4.1 l.9(—45 21%) 7.1 1.7 3.9 1.5 (—46 15%)
prot >6 g/24 hr (N = 6) 7.3 1.3 4.1 1.8 (—45 19%) 7.6 1.6 4.0 1.2 (47 11%)
prot <6 g/24 hr(N = 6) 4.7 1.4 1.5 0.8 (—69 18%) 4.6 0.9 2.2 1.0 (—52 21%)
low and higher dose of lisinopril (from 362 99 to 388 95 and
390 105 mI/mm, respectively, both P < 0.05). The fall in FF
(from 21.3 3.3 to 19.8 3.9%) on indomethacin reached
significance (P < 0.05), while FF fell from 21.6 3.7% to 19.9
3.7% (NS) on low dose lisinopril and to 18.7 3.2% (P <
0.001) on the higher dose. RVR rose by 22 21% (P < 0.05) on
indomethacin, and fell during low and higher dose lisinopril by
10 10% (P < 0.05) and 14 9% (P < 0.01), respectively.
The patients adhered adequately to the dietary instructions
during the study, since urinary sodium and urea excretion were
constant. Body weight increased during indomethacin from 78.9
15.3 to 79.7 14.7 kg (P <0.05), whereas it fell during the
low and higher dose lisinopril from 78.2 15.0 to 77.0 14.2 kg
and 76.7 14.5 kg (both P < 0.01), respectively. The rise in
serum albumin on indomethacin from 32 6 to 35 5 g/liter (P
<0.01), was not significantly different from the increase on the
higher dose of lisinopril from 32 6 to 34 5 g/liter (P <0.05).
Serum cholesterol fell from 7.7 1.2 to 6.6 1.2 mmol/liter (P
< 0.001) on indomethacin, and from 7.3 1.2 to 6.8 1.0
mmol/liter (NS) on the higher lisinopril dose. Serum potassium
rose from 4.6 0.3 to 5.0 0.3 mmol/liter (P < 0.001) on
indomethacin and from 4.6 0.3 to 4.9 0.3 mmol/liter (P <
0.05) on the higher dose of lisinopril. On both drugs a temporary
rise >1.0 mmollliter was observed in one patient.
Five out of 12 patients had pronounced complaints of dizzi-
ness and gastric pain or nausea during the indomethacin period.
During lisinopril one patient had transient hypotensive com-
plaints, one had minor muscle cramps, and one had dry cough.
All the other patients reported subjective improvement on
lisinopril.
Although part of the interindividual variability in the antipro-
teinuric effect of lisinopril may thus be due to the differences in
lisinopril dosage, there is still quite a variability in the individual
antiproteinuric response on ACE inhibition. To evaluate the
influence of pretreatment parameters like the blood pressure
level, the degree of renal function impairment and the level of
proteinuria on the antiproteinuric response, the results on
proteinuria in the 12 patients are presented stratified according
to the initial MAP, GFR and proteinuria, respectively (Table 3).
In patients who received different doses of lisinopril, the data of
the higher dose of lisinopril are given. The antiproteinuric effect
of both indomethacin and lisinopril was virtually similar
whether pretreatment MAP was more or less than 100 mm Hg.
When stratified according to GFR, control proteinuria appeared
to be higher (P < 0.01) in the group of patients with lower GFR
(mean: 54 12 mI/mm) as compared to the patients with higher
GFR (mean: 94 21 mI/mm), but the changes in proteinuria
during treatment were not significantly different in both groups.
The effect of lisinopril on proteinuria did also not differ whether
pretreatment protein excretion was more or less than 6 g124 hr.
Moreover, there was no correlation between the antiproteinuric
effect of lisinopril and the pretreatment MAP (r = 0.31, NS),
GFR (r =
—0.03, NS), or proteinuria (r = 0.13, NS).
Thus, there is no significant influence of initial blood pressure
level, degree of renal function impairment, or proteinuria on the
antiproteinuric effect of lisinopril.
Part 3
To study the influence of sodium intake on the antiproteinuric
effect of ACE inhibition, 9 of the 12 patients continued lisinopril
into a next study period in which sodium intake was switched
from 50 to 200 mmol/day. The median duration of this study
period was eight weeks (range 6 to 12). After the test day the
sodium intake was restricted again to 50 mmol/day, during
which no further test day was performed. Meanwhile there was
no change in lisinopril dose. As measured from the urinary
sodium excretion, daily sodium intake increased from 84 28,
83 36 and 76 9 mmol during the low salt intake in the
pretreatment, control and lisinopril period, respectively, to 182
35 mmol/day in the lisinopril period with high salt intake.
During the final low salt intake sodium excretion was 86 25
mmol/day. The effects on proteinuria, as presented in Figure 3,
were remarkable. Proteinuria in these nine patients was 6.4
2.4 g/24 hr without therapy and 6.4 2.0 g124 hr during
a-methyldopa, and was subsequently reduced by 52 14% (P
< 0.001) to 3.1 1.4 g/24 hr on lisinopril during the salt
restricted diet. During the high salt intake, proteinuria in-
creased to 5.9 3.0 g/24 hr (P < 0.01) which did not differ
significantly from proteinuria during the control period. After
changing again to the low salt intake proteinuria decreased to
3.2 1.3 g/24 hr. As was to be expected, blood pressure was
also influenced by the change in salt intake during ACE
inhibition. On a sodium restricted diet, MAP was 104 11 mm
Hg without therapy and 92 6 mm Hg on a-methyldopa in
these patients, and was lowered further by 5 5% (P < 0.05) to
87 8 mm Hg on lisinopril. After switching to a high sodium
diet on the same dose of lisinopril, MAP increased by 3 3% (P
<0.05) to 89 8 mm Hg, which did not differ significantly from
MAP during the control period on a-methyldopa. On low
sodium intake MAP decreased again to 87 8 mm Hg. These
changes in MAP did not correlate with the concomitant changes
in proteinuria on different sodium intake. GFR fell by 7 4%
from 71 21 to 67 22 mI/mm (P < 0.01) on lisinopril during
a low sodium diet and rose again to 71 25 mI/mm after
switching to high salt intake. ERPF and FF however, did not
change significantly after changing the diet during lisinopril.
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Fig. 3. Proteinuria in 9 patients who switched
from low to high sodium intake during lisinopril.
The bars represent the mean with SEM of protein
excretion in the 24-hour urine collections in the
last month of the different study periods. The
wide bars represent the mean of three
consecutive urine samples prior to the testdays,
whereas the narrow bars represent the values of
the two preceding ambulatory visits.
Body weight decreased by 2 1% (P < 0.001) on lisinopril
during salt restriction, increased by 2 2% (P < 0.05) on high
salt intake, and decreased again on low salt intake. In five of
nine patients edema developed during high salt intake, which
resolved again after changing back to salt restriction.
Thus, proteinuria was halved on lisinopril during sodium
restriction, while this antiproteinuric effect virtually disap-
peared after changing to a high salt intake.
Discussion
The present study shows that the ACE inhibitor lisinopril has
an antiproteinuric effect comparable to the NSAID indometh-
acm in patients with overt proteinuria of various origin. This
effect of the ACE inhibitor appears to be dose related and
dependent on adequate sodium restriction. The proteinuria
lowering effect of lisinopril is neither determined by the pre-
existent blood pressure, nor by the degree of renal function
impairment, nor by the level of proteinuria.
Several studies have recently reported on the antiproteinuric
effect of ACE inhibitors [4—10]. However, these studies were
performed in hypertensive patients, usually with renal function
impairment [4, 5, 7—91, and some with only little proteinuria [6,
7, 101. In contrast, in the present study the ACE inhibitor
lisinopril is prescribed because of overt proteinuria in predom-
inantly normotensive patients, with normal as well as with
impaired renal function. It should be noted that not in all studies
on this subject was ACE inhibition found to have an antipro-
teinuric effect [11—13]. Moreover, in all studies in which a
proteinuria lowering effect of ACE inhibition was shown, there
was a wide variability in individual response, ranging from a
rise to almost complete disappearance of proteinuria. The
present study does not show any influence of the preexisting
blood pressure level, nor of the degree of renal function
impairment and proteinuria on the antiproteinuric effect. How-
ever, the effect appears to be dose related and strongly depen-
dent on the dietary sodium restriction. It is noteworthy that in
some patients it took several weeks before the reduction in
proteinuria had reached a stable level during lisinopril. This
time dependency should be considered when evaluating the
effect of an ACE inhibitor on proteinuria, and forms a potential
drawback in interpreting a dose response effect. Although in
this study no control periods were included between the study
periods with different lisinopril doses or with different dietary
sodium intake, a carry-over effect seems unlikely. Firstly, the
effect on proteinuria had to be stable in each study period
before switching to the next period. It appears from Figures 2
and 3 that urinary protein excretion during the last month of
each study period indeed did not further change. Secondly, we
observed a good recovery with respect to the effect on protein-
uria after switching from high to low salt intake again. Both the
dose-related and salt-intake-related phenomena may therefore
in part explain the variability in antiproteinuric response re-
ported in the literature: a fixed dose of the ACE inhibitor was
only used in a few studies in which concomitant antihyperten-
sive drugs were continued [5, 81, and sodium intake was usually
not (uniformly) restricted [4—8, 10—131, and not evaluated [4—
13].
It is an intriguing observation that the increase in sodium
intake virtually abolishes the antiproteinuric effect of ACE
inhibition. Although we did not evaluate the effect of changes in
Low sa't Low salt High salt Low salt
methyldopa [sinopriI lisinopril lisinopril
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salt intake on proteinuria in a control period, a prior study in
patients with nephrotic syndrome showed that volume deple-
tion with diuretic therapy does not influence urinary protein
excretion [15]. It is known that both the systemic blood
pressure lowering effect and the renal hemodynamic effects of
ACE inhibition are enhanced by sodium depletion [19]. If the
antiproteinuric effect of ACE inhibition is caused by these
hemodynamic changes, it is thus conceivable that this effect is
also or even more dependent on sodium balance. We observed
an association between changes in urinary protein excretion
and in GFR during the different study periods. When protein-
uria was lowered, a small fall in GFR occurred as well, which
was also abolished on a high salt intake. This may well favor the
assumption that the antiproteinuric effect of ACE inhibition is
due to a lowering of the intraglomerular capillary pressure [5, 6,
91. The latter could also be reflected by the observed fall in FF
due to a predominantly postglomerular vasodilation on ACE
inhibition [20].
Apart from these renal hemodynamic effects, the systemic
blood pressure lowering during ACE inhibition could well
contribute to the antiproteinuric effect. In the present study we
did not fully exclude this possibility, as our attempt to achieve
a similar blood pressure during the control periods and indo-
methacin treatment by the use of a-methyldopa failed: lisinopril
induced a small but significant further reduction in blood
pressure. However, a 10% reduction in blood pressure by
a-methyldopa as compared to the pretreatment period did not
lower proteinuria, while a further fall in blood pressure by 3%
and 7% on low and higher dose lisinopril, respectively, coin-
cided with a 27% and 50% reduction in proteinuria. Likewise, a
3% rise in blood pressure during lisinopril in the high salt
condition was associated with a nearly doubling of proteinuria.
Moreover, there were no correlations between these minor
changes in blood pressure and the concomitant changes in
proteinuria during the study. Thus, the changes in proteinuria
by ACE inhibition and by changing salt intake during this study
cannot solely be ascribed to changes in systemic blood pres-
sure. The antiproteinuric effect of ACE inhibition is more likely
to be due to specific renal effects that only emerge on such a
dose of lisinopril on which also blood pressure is reduced. The
latter, in turn, may contribute to the lowering of proteinuria.
Except for hemodynamic changes, the effect of ACE inhibition
on proteinuria may also be caused by changes in glomerular
permeability to macromolecules. Further studies are needed to
investigate the mechanism of the antiproteinuric effect of ACE
inhibition.
Until now, for symptomatic treatment of the nephrotic syn-
drome only NSAID's like indomethacin are available [14, 15],
which however induce unfavorable effects on renal function
[14—16] and have side effects as also observed in the present
study. ACE inhibitors like lisinopril do not have these effects,
but these agents, on the other hand, lower the blood pressure.
However, this antihypertensive effect did not induce unfavor-
able side effects in the normotensive proteinuric patients in the
present study. Serum potassium increased on both indometh-
acm and lisinopril, which could, when necessary, be adjusted
acceptably with dietary potassium restriction. Indomethacin
may induce sodium retention [16] as reflected by the increase in
body weight in the present study, while on lisinopril body
weight decreased due to the diuretic properties of ACE inhibi-
tion [21]. On both therapies serum albumin increased and serum
cholesterol fell. Thus, in this study lisinopril appears to be an
attractive alternative in symptomatic treatment of overt pro-
teinuria. Moreover, proteinuria is found to be a poor prognostic
factor in renal disease [22, 23], and reducing proteinuria could
possibly prevent progression of renal damage and function
decline. Indeed, in proteinuric patients, NSAID treatment
ameliorated renal function deterioration in patients in whom
proteinuria was reduced by this treatment, as has been de-
scribed in retrospective reports [24—26]. Both in human [11, 12]
and in experimental chronic renal failure [27, 28], there is
accumulating evidence that ACE inhibition also ameliorates
renal function decline, even without lowering established pro-
teinuria [11, 12, 29, 30].
We conclude from this study that the ACE inhibitor lisinopril
has an antiproteinuric effect in patients with overt proteinuria
due to renal disease of various origin. This effect appears to be
dose related and in some patients also time related, and is
strongly dependent on sodium restriction, whereas it does not
depend on the initial blood pressure, the degree of renal
function impairment, or the level of proteinuria. The proteinuria
lowering effect is comparable with the effect of the NSAJD
indomethacin, while during ACE inhibition adverse effects are
less and the renal hemodynamic profile appears to be more
favorable. It is of interest to further study whether the combi-
nation of an ACE inhibitor with a N SAID has an additive effect
on urinary protein loss. Moreover, it will be a challenge to
establish the beneficial long-term effects of ACE inhibition on
deterioration of renal function in chronic renal disease.
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